Mallinckrodt has agreed to fund a clinical trial conducted by US researchers to assess the use of its inhaled nitric oxide therapy, INOmax, to treat lung complications in Covid-19 patients.
The company would offer funding support, as well as INOmax, for the investigator-initiated trial at Massachusetts General Hospital.
The primary objective of the study is the potential efficacy of inhaled nitric oxide in reversing abnormally low oxygen levels in the blood of Covid-19 patients with severe lung complications.
Share this article
